RxNews Recap for Thursday 12-17-09 Print E-mail
By Mary Davila   
Thursday, 17 December 2009 19:24

Below is a list of the companies that made news in the healthcare sector on Thursday, December 17, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has raised approximately $3.2 million in gross proceeds from a private placement of approxiately 5.0 million units.

Ascendant Solutions, Inc.  (Pink Sheets: ASDS) today announced its results for the third quarter of fiscal 2009.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Dr. Lesley Russell, Executive Vice President and Chief Medical Officer of Cephalon, has been elected to AMAG’s Board of Directors, effective immediately.

Facet Biotech Corporation (NASDAQ: FACT) today commented on the filing by Biogen Idec Inc. (NASDAQ: BIIB) disclosing that the stockholders of Facet Biotech have rejected Biogen Idec's unsolicited tender offer and that Biogen Idec has terminated its tender offer.

Glowpoint, Inc. (OTCBB: GLOW), a leading provider of advanced video communications solutions, and MMC Worldwide (MMCW), a provider of high-quality video production and post-production services for global healthcare and education communities, today announced an agreement to offer enhanced video solutions to the medical and pharmaceutical industries.

Hop-on, Inc. (PINKSHEETS: HPNN) and USACIG, Inc. announced today it executed contracts with E-Exobus, Inc. for the distribution of USACIG's The Electric Cigarette™ and the Electric Cigar™ in New York, Michigan, Ohio and Illinois.

ICON Plc (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. John Climax will retire as Chairman of ICON Plc as of 31st December 2009, but will remain a board member.

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, announced today the appointment of Suzanne Cadden as Vice President of Regulatory Affairs & Quality.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Neurogen Corporation (NASDAQ: NRGN) announced today they have amended their merger agreement to increase the merger consideration payable.

Neurogen Corporation (NASDAQ: NRGN) announced today that it received a NASDAQ staff determination letter on December 11, 2009, notifying the company that it has not regained compliance, during a prescribed period, with NASDAQ Listing Rule 5450(a)(1), which requires the stock of listed companies to trade at or above $1.00 per share.

NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced that it has signed an agreement to lease its facility in East Windsor, NJ, commencing February 1, 2010.

PPD, Inc. (Nasdaq: PPDI) today announced it has entered into an exclusive alliance with DiabetesAmerica™, a provider of comprehensive diabetes care services based in Houston, Texas.

Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) today announced the appointment of Sandra Lauterbach to Vice President, Sales and Commercial Affairs.

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) today announced that Dean Jonathan Mitchell has been appointed to its board of directors. Mitchell’s appointment brings the number of Talecris board members to ten.

Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has determined the final purchase price offered by the company pursuant to its previously announced tender offer (the “Offer”) to purchase for cash any and all of its outstanding 2.50% Convertible Senior Notes due 2023 (the “Convertible Notes”).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus